Identifying a typology of men who use anabolic androgenic steroids (AAS)

Zahnow, Renee, McVeigh, Jim, Bates, Geoff, Hope, Vivian, Kean, Joseph, Campbell, John and Smith, Josie (2018) Identifying a typology of men who use anabolic androgenic steroids (AAS). The International journal on drug policy, 55 105-112. doi:10.1016/j.drugpo.2018.02.022

Author Zahnow, Renee
McVeigh, Jim
Bates, Geoff
Hope, Vivian
Kean, Joseph
Campbell, John
Smith, Josie
Title Identifying a typology of men who use anabolic androgenic steroids (AAS)
Journal name The International journal on drug policy   Check publisher's open access policy
ISSN 1873-4758
Publication date 2018-03-08
Sub-type Article (original research)
DOI 10.1016/j.drugpo.2018.02.022
Open Access Status Not yet assessed
Volume 55
Start page 105
End page 112
Total pages 8
Publisher Elsevier B.V.
Language eng
Subject 2701 Medicine (miscellaneous)
2719 Health Policy
Abstract Despite recognition that the Anabolic Androgenic Steroid (AAS) using population is diverse, empirical studies to develop theories to conceptualise this variance in use have been limited.

In this study, using cluster analysis and multinomial logistic regression, we identify typologies of people who use AAS and examine variations in motivations for AAS use across types in a sample of 611 men who use AAS.

The cluster analysis identified four groups in the data with different risk profiles. These groups largely reflect the ideal types of people who use AAS proposed by Christiansen et al. (2016): Cluster 1 (You Only Live Once (YOLO) type, n = 68, 11.1%) were younger and motivated by fat loss; Cluster 2 (Well-being type, n = 236, 38.6%) were concerned with getting fit; Cluster 3 (Athlete type, n = 155, 25.4%) were motivated by muscle and strength gains; Cluster 4 (Expert type, n = 152, 24.9%) were focused on specific goals (i.e. not 'getting fit').

The results of this study demonstrate the need to make information about AAS accessible to the general population and to inform health service providers about variations in motivations and associated risk behaviours. Attention should also be given to ensuring existing harm minimisation services are equipped to disseminate information about safe intra-muscular injecting and ensuring needle disposal sites are accessible to the different types.
Keyword Anabolic steroids
Harm minimisation
Image and performance enhancing drugs
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Pubmed Import
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 14 Mar 2018, 10:02:02 EST